Epitranscriptome (m6A/m5C) Mapping & Analysis Service
Creative Biolabs delivers a sophisticated analytical framework that transcends basic sequencing to provide high-resolution, single-base maps of m6A, m5C, and m1A modifications. By analyzing the entire transcriptome, we enable researchers to pinpoint the regulatory drivers of cellular transformation. Our service quantifies site-specific modification levels and correlates them with mRNA stability, translational efficiency, and RNA-protein interaction dynamics.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The New Era of Cancer Epigenetics: Why the Epitranscriptome?
While traditional epigenetics focuses on DNA and histones, epitranscriptomics offers a dynamic layer of gene control through chemical RNA modifications. In oncogenesis, dysregulated writers, erasers, and readers drive functional plasticity in ncRNAs (lncRNA, tRNA, rRNA), influencing gene silencing and metabolic reprogramming via "tRNA logic." This "secondary code" modulates RNA-RBP interactions, often enhancing the stability of metastatic oncogenic transcripts like MALAT1 and HOTAIR. Notably, m6A reduction characterizes aggressive tumor subtypes and altered translational efficiency. Creative Biolabs maps these epitranscriptomic landscapes to identify therapeutic targets and subtype-specific signatures hidden within the RNA regulatory layer.
Comprehensive RNA Modification Profiling
Creative Biolabs provides an expansive suite of specialized mapping and analytical solutions tailored to the unique requirements of cancer research.
m6A Methylation Mapping (MeRIP-Seq)
We utilize high-affinity antibodies for transcriptome-wide enrichment and sequencing of N6-methyladenosine sites. This enables researchers to precisely identify oncogenic methylation peaks and characterize regulatory domains essential for transcript stability and cancer progression.
m5C Single-Base Mapping
Our platform employs bisulfite-free enzymatic conversion and direct RNA sequencing to resolve 5-methylcytosine positions. We achieve base-pair precision in both coding mRNA and structural tRNAs to reveal metastatic signatures.
Contact our scientific team today to discuss how we can customize a mapping strategy for your specific cancer model.
Workflow
Our systematic workflow ensures high data integrity and reproducibility across diverse research models, from cell lines to archived specimens.
Publication
This publication introduces CHEUI (CH3 estimation using ionic current), a computational tool that enables transcriptome-wide prediction of m6A and m5C RNA modifications at single-molecule resolution from nanopore direct RNA sequencing data. By analyzing ionic current signals with a two-stage neural network, CHEUI identifies both modification types within the same sample without requiring knockout controls. The method reveals a previously unexplored co-occurrence of m6A and m5C modifications in individual mRNA molecules, offering new avenues to study the functional complexity of the epitranscriptome.
Fig.1 Detection of m6A and m5C modifications in cell lines. 1
Why Choose Us?
Creative Biolabs stands at the forefront of RNA epigenetics, offering unique technical advantages such as Nanopore direct-RNA sequencing to eliminate PCR-induced biases. Our specialized expertise in ncRNA mapping ensures that regulatory marks on tRNAs and lncRNAs are fully characterized. We integrate "writer-reader-eraser" axis analysis to provide a mechanistic view of tumor microenvironment plasticity. Our expertise is supported by Published Data indicating that high-precision epitranscriptome mapping can identify diagnostic signatures with significantly higher sensitivity than standard transcriptomics alone.
Experience the Creative Biolabs Advantage - Get a Personalized Quote Today
FAQs
What is the minimum amount of RNA required for m6A mapping?
We typically require 1-2 µg of total RNA, though we offer optimized low-input protocols for specific research applications requiring as little as 500ng.
Does Creative Biolabs offer single-base resolution for m5C?
Yes, we utilize enzymatic conversion and nanopore sequencing to achieve base-pair resolution across mRNA and non-coding RNA species.
How do you handle highly structured RNAs like tRNAs?
We use specialized reverse transcriptases and buffer systems designed to overcome structural interference, ensuring complete coverage of the tRNA/rRNA epitranscriptome.
Customer Review
-
Unmatched Resolution in ncRNA
Using Creative Biolabs' m5C mapping in our research has significantly facilitated our understanding of tRNA stability in metastatic models. The nanopore integration provided single-molecule insights we couldn't achieve through traditional bisulfite sequencing. – Dr. A***n H
-
Superior Bioinformatics Support
The correlation analysis between m6A writers and immune infiltration using Creative Biolabs' service has significantly improved our immuno-oncology project. Their team's interpretation of the integrated TCGA-level data was invaluable for our target validation. – Prof. S***l M
Related Services
Gene Expression Profiling Service
Creative Biolabs provides comprehensive gene expression profiling using transcriptomics, microarrays, and dPCR/qPCR. Our customized solutions ensure high-fidelity quantification and bioinformatics optimization for every research objective.
Learn More →
Treg Subpopulation Expression Profiling
Creative Biolabs provides bulk and single-cell Treg profiling to decode immune regulation. We integrate RNA-seq, differential expression, and immunoinformatics to reveal functional mechanisms and therapeutic targets.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs offers a world-class platform for epitranscriptome mapping and analysis, providing the high-resolution data necessary to navigate the complexities of cancer epigenetics. From m6A peak detection to m1A single-base resolution, our services empower your drug discovery and biomarker research with precision and scientific rigor.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Acera Mateos, P., et al. "Prediction of m6A and m5C at single-molecule resolution reveals a transcriptome-wide co-occurrence of RNA modifications." Nature Communications 15.1 (2024): 3899. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41467-024-47953-7
For Research Use Only | Not For Clinical Use
Download our brochure